AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22049995 — intervention group
Group type: COMPARATOR
Intervention: Self-administered CPQ(11-14)
Number of subjects: 180
Study 20546209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 microg/kg desmopressin
Number of subjects: 75
Study 20546209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg desmopressin
Number of subjects: 75
Study 20546209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18492739 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery
Number of subjects: 60
Study 18492739 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous chest drain insertion and urokinase
Number of subjects: 60
Study 15969858 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 15969858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14757913 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 mg betahistine
Number of subjects: 12
Study 10354291 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (100 microgram/kg desirable body weight, subcutaneously every 12 hours for up to 14 days)
Number of subjects: 72
Study 10354291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 10354291 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 72
Study 8760703 — intervention group
Group type: EXPERIMENTAL
Intervention: Early induction group (induction the following morning after PROM)
Number of subjects: 1385
Study 8760703 — intervention group
Group type: EXPERIMENTAL
Intervention: Late induction group (induction two days later)
Number of subjects: 1385
Study 8760703 — intervention group
Group type: COMPARATOR
Intervention: Both groups (induction with oxytocin if no spontaneous contractions or if chorioamnionitis or fetal distress)
Number of subjects: 1385
Study 2014943 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (325 mg, alternate-day)
Number of subjects: 333
Study 2014943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 6385507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg cimetidine daily in four separate doses (q.i.d.)
Number of subjects: 149
Study 6385507 — intervention group
Group type: COMPARATOR
Intervention: 400 mg cimetidine twice a day (b.i.d.)
Number of subjects: 149
Study 6385507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (q.i.d. and b.i.d.)
Number of subjects: 149
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Household costs associated with P. vivax malaria treatment
Number of subjects: 0
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Productivity losses as a household cost component
Number of subjects: 0
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care provider costs for routine care
Number of subjects: 0
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test
Number of subjects: 0
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of fluorescent spot test
Number of subjects: 0
Study 29022844 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (photobiomodulation)
Number of subjects: 42
Study 29022844 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 42
Study 26437144 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential avoidance
Number of subjects: 184
Study 26437144 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 184
Study 24462489 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching television while eating (TV)
Number of subjects: 0
Study 24462489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating with a single snack type with TV
Number of subjects: 0
Study 24462489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating with TV
Number of subjects: 0
Study 24462489 — intervention group
Group type: COMPARATOR
Intervention: Eating without TV
Number of subjects: 0
Study 22210481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral HIV risk reduction intervention (E‐CB)
Number of subjects: 222
Study 22210481 — intervention group
Group type: COMPARATOR
Intervention: Health promotion condition (HPC)
Number of subjects: 222
Study 20652432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna oil (210 mg EPA, 30 mg DPA, 810 mg DHA)
Number of subjects: 30
Study 20652432 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (340 mg EPA, 230 mg DPA, 450 mg DHA)
Number of subjects: 30
Study 20652432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunola oil)
Number of subjects: 30
Study 22316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (immediate measurement of thyrotropin and free T(4) levels)
Number of subjects: 21
Study 22316443 — intervention group
Group type: COMPARATOR
Intervention: Control group (serum stored, measurements obtained shortly after delivery)
Number of subjects: 21
Study 22316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 21
Study 22316443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 15986590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral fractures prevalence
Number of subjects: 425
Study 15986590 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of osteoporosis
Number of subjects: 425
Study 15986590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractured vertebrae analysis
Number of subjects: 425
Study 12521404 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (SC)
Number of subjects: 66
Study 12521404 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 66
Study 10493085 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-50 mg daily
Number of subjects: 92
Study 10493085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 10493085 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 92
Study 9112194 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoroperhydrophenanthrene
Number of subjects: 111
Study 9112194 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoroperhydrophenanthrene in cases complicated by proliferative vitreoretinopathy
Number of subjects: 111
Study 1767251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin dosed twice daily
Number of subjects: 206
Study 1767251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin dosed three times daily
Number of subjects: 206
Study 6808854 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing the femoral shaft cavity with carbon dioxide
Number of subjects: 0
Study 6808854 — intervention group
Group type: COMPARATOR
Intervention: Insertion of bone cement
Number of subjects: 0
Study 28741050 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 0
Study 28741050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28741050 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 with ACE inhibitors/ARBs
Number of subjects: 0
Study 28741050 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ACE inhibitors/ARBs
Number of subjects: 0
Study 27787876 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) intervention
Number of subjects: 1635
Study 27787876 — intervention group
Group type: COMPARATOR
Intervention: Health education-based successful aging (SA) intervention
Number of subjects: 1635
Study 25716539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg single oral dosage
Number of subjects: 0
Study 25716539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23261097 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation during colonoscope intubation (98 patients)
Number of subjects: 193
Study 23261097 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation during colonoscope intubation (97 patients)
Number of subjects: 193
Study 23261097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CO(2) and air) post-procedure
Number of subjects: 193
Study 20171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 400
Study 18794642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 100
Study 18794642 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100
Study 18794642 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study 18794642 — intervention group
Group type: COMPARATOR
Intervention: Control (Clozapine, Haloperidol)
Number of subjects: 100
Study 15665769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol) 40 mg/day or 80 mg/day
Number of subjects: 1050
Study 15665769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 12973839 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, fruit and vegetable-enriched dietary intervention
Number of subjects: 399
Study 12973839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 399
Study 10423657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (0.2 mg/kg once daily for 28 days)
Number of subjects: 80
Study 10423657 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (0.2 mg/kg once daily for 28 days)
Number of subjects: 80
Study 10423657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine and Loratadine
Number of subjects: 80
Study 8538704 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (SmithKline Beecham)
Number of subjects: 14751
Study 8538704 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (Chiron Biocine)
Number of subjects: 14751
Study 8538704 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell DTP vaccine
Number of subjects: 14751
Study 8538704 — intervention group
Group type: COMPARATOR
Intervention: Acellular DTP vaccines
Number of subjects: 14751
Study 8538704 — intervention group
Group type: COMPARATOR
Intervention: Acellular vaccines
Number of subjects: 14751
Study 1866164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic treatment (Cyclophosphamide, Vincristine, Ftorafur) for 3 months for Group 1 and lifelong systemic treatment for Group 2.
Number of subjects: 36
Study 1866164 — intervention group
Group type: COMPARATOR
Intervention: Control group (67 patients) who had not received chemotherapeutic treatment.
Number of subjects: 36
Study 7048748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonazolac-Ca (200 mg three times daily)
Number of subjects: 40
Study 7048748 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250 mg twice daily plus 1 placebo capsule)
Number of subjects: 40
Study 29463947 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 132
Study 29463947 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 132
Study 27052127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuliser technique assessment using nebuliser-specific checklists.
Number of subjects: 32
Study 27052127 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular evaluation by the CF-team.
Number of subjects: 32
Study 25495887 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 140
Study 25495887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 22809907 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasojejunal nutrition
Number of subjects: 181
Study 22809907 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric nutrition
Number of subjects: 181
Study 20050995 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27
Study 20050995 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 27
Study 18679606 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xufu Zhuyu Decoction (XFZY) plus conventional comprehensive Western medicine
Number of subjects: 60
Study 18679606 — intervention group
Group type: COMPARATOR
Intervention: Conventional comprehensive Western medicine
Number of subjects: 60
Study 15939844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (9-minute cognitive intervention designed to reduce novelty, increase cognitive coping, and provide a sense of control)
Number of subjects: 28
Study 15939844 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard introduction)
Number of subjects: 28
Study 15939844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 28
Study 12227873 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.1% w/w and erythromycin 4.0% w/w gel (Double Strength Isotrexin) once daily
Number of subjects: 188
Study 12227873 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide 5.0% w/w and erythromycin 3.0% w/w gel (Benzamycin) twice daily
Number of subjects: 188
Study 12227873 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin/erythromycin gel
Number of subjects: 188
Study 12227873 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide/erythromycin gel
Number of subjects: 188
Study 10215736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1 g b.d. for 14 days
Number of subjects: 16
Study 10215736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7533345 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 50
Study 7533345 — intervention group
Group type: COMPARATOR
Intervention: CsA (cyclosporine)
Number of subjects: 50
Study 2213396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension at a dosage of 30 to 40 mg/kg/day
Number of subjects: 92
Study 2213396 — intervention group
Group type: COMPARATOR
Intervention: Aspirin at a dosage of 60 to 80 mg/kg/day
Number of subjects: 92
Study 2213396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension (30, 40, and 50 mg/kg/day) in a 24-week open trial
Number of subjects: 92
Study 2213396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension
Number of subjects: 92
Study 352972 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam with phenytoin and phenobarbital
Number of subjects: 24
Study 352972 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 31721131 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with better ejection fraction (HFbEF)
Number of subjects: 399
Study 31721131 — intervention group
Group type: COMPARATOR
Intervention: Extended recovery
Number of subjects: 399
Study 31721131 — intervention group
Group type: COMPARATOR
Intervention: Late recovery
Number of subjects: 399
Study 31721131 — intervention group
Group type: COMPARATOR
Intervention: Transient recovery
Number of subjects: 399
Study 31721131 — intervention group
Group type: EXPERIMENTAL
Intervention: HFbEF
Number of subjects: 399
Study 31721131 — intervention group
Group type: COMPARATOR
Intervention: Late and extended recovery
Number of subjects: 399
Study 31888938 — intervention group
Group type: EXPERIMENTAL
Intervention: Short text messages three times a week for 6 months designed to improve medication adherence.
Number of subjects: 200
Study 31888938 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-health-related messages).
Number of subjects: 200
Study 28522181 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg intravenous)
Number of subjects: 192
Study 28522181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 192
Study 28522181 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 192
Study 28522181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 26400691 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (PIP) - includes Standard Care (SC) and home visits by community health workers (M=11 visits)
Number of subjects: 1238
Study 26400691 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) - routine antenatal care
Number of subjects: 1238
Study 23356861 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT intervention (self-management intervention involving an information guidebook, tailored access to local resources, and telephone support)
Number of subjects: 0
Study 23356861 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 21849011 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue medication (Group A)
Number of subjects: 108
Study 21849011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month additional medication (Group B)
Number of subjects: 108
Study 21849011 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month additional medication (Group C)
Number of subjects: 108
Study 19893105 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 12
Study 19893105 — intervention group
Group type: COMPARATOR
Intervention: Dual associative stimulation (DAS)
Number of subjects: 12
Study 17449984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling of the primary (key) MTrP in the infraspinatus muscle on one side
Number of subjects: 14
Study 17449984 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated) side
Number of subjects: 14
Study 15475126 — intervention group
Group type: EXPERIMENTAL
Intervention: High contact hip stress
Number of subjects: 103
Study 15475126 — intervention group
Group type: COMPARATOR
Intervention: Healthy hips
Number of subjects: 103
Study 11482041 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 85
Study 11482041 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus antibiotic placebo
Number of subjects: 85
Study 11482041 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine placebo (after initial treatment)
Number of subjects: 85
Study 11482041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (after initial treatment)
Number of subjects: 85
Study 9824409 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (subcutaneous immunotherapy) for birch pollen for 12, 24, or 36 months
Number of subjects: 49
Study 9824409 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (subcutaneous immunotherapy) for birch pollen
Number of subjects: 49
Study 9824409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 49
Study 7656887 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU vitamin A
Number of subjects: 199
Study 7656887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 2496052 — intervention group
Group type: EXPERIMENTAL
Intervention: abortive therapy with ergotamine tartrate plus caffeine (standard abortive therapy)
Number of subjects: 34
Study 2496052 — intervention group
Group type: COMPARATOR
Intervention: standard abortive therapy accompanied by a brief educational intervention
Number of subjects: 34
Study 970521 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 50
Study 970521 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study 31613842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity breastfeeding at 6 months
Number of subjects: 462
Study 31613842 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (dichotomous indicator)
Number of subjects: 462
Study 31613842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding intensity at 6 months
Number of subjects: 462
Study 30266345 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 49
Study 30266345 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study 27444633 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklets for students containing information on mental health self-management and help seeking
Number of subjects: 14690
Study 27444633 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding for mental health support as part of a national mental health initiative
Number of subjects: 14690
Study 26182059 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based exergame, played once or twice a week, up to a total of 24 times
Number of subjects: 57
Study 26182059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 57
Study 23924279 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTO intervention (manual of text and tools; face-to-face training; onsite technical assistance)
Number of subjects: 12
Study 23924279 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTO intervention (with highest number of technical assistance hours)
Number of subjects: 12
Study 23924279 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine operations)
Number of subjects: 12
Study 21722958 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 206
Study 21722958 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 50 mg
Number of subjects: 206
Study 21722958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 18848460 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital group (electronic measure of pleural air leak using Millicore AB DigiVent chest drainage system)
Number of subjects: 61
Study 18848460 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (standard water seal pleural chamber)
Number of subjects: 61
Study 16734597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall RS1 leukocyte removal filter
Number of subjects: 18
Study 16734597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall LipiGuard fat removal filter
Number of subjects: 18
Study 16734597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresenius Biofil 02 leukocyte removal filter
Number of subjects: 18
Study 12677952 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual + basic education and support
Number of subjects: 1050
Study 12677952 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual + intensive education and support
Number of subjects: 1050
Study 12677952 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1050